➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Johnson and Johnson
Dow
Express Scripts
Boehringer Ingelheim

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,561,277


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,561,277
Title:Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).
Inventor(s): Sawa; Shirou (Hyogo, JP), Fujita; Shuhei (Hyogo, JP)
Assignee: SENJU PHARMACEUTICAL CO., LTD. (Osaka, JP)
Application Number:14/502,014
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,561,277
Patent Claims: 1. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; wherein the hydrate is at least one selected from a 1/2 hydrate, 1hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol and is present in said liquid preparation in an amount sufficient to stabilize said first component; wherein said stable liquid preparation is formulated for ophthalmic administration; wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease; and wherein said inflammatory disease is blepharitis, conjunctivitis, scleritis or postoperative inflammation.

2. The method according to claim 1, wherein said inflammatory disease is blepharitis, conjunctivitis or scleritis.

3. The method according to claim 1, wherein said inflammatory disease is postoperative inflammation.

4. The method according to claim 1, wherein the stable aqueous liquid preparation further comprises a quaternary ammonium salt.

5. The method according to claim 1, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.

6. The method according to claim 1, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %.

7. The method according to claim 1, wherein the pH is from about 7.5 to about 8.5.

8. The method according to claim 1, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, (b) tyloxapol, (c) boric acid, (d) sodium tetraborate, (e) EDTA sodium salt, (f) benzalkonium chloride, (g) polyvinylpyrrolidone, and (h) sodium sulfite, wherein said liquid preparation is formulated for ophthalmic administration, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 w/v % to about 0.1 w/v %, and wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %.

9. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; wherein the stable aqueous liquid preparation is characterized in that greater than about 90% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks; wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease; and wherein said inflammatory disease is blepharitis, conjunctivitis, scleritis or postoperative inflammation.

10. The method according to claim 9, wherein said inflammatory disease is blepharitis, conjunctivitis or scleritis.

11. The method according to claim 9, wherein said Inflammatory disease is postoperative inflammation.

12. The method acording to claim 9, wherein the stable aqueous liquid preparation further comprises a quaternary ammonium salt.

13. The method according to claim 9, wherein the stable aqueous liquid preparation is characterized in that greater than about 92% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks.

14. The method according to claim 9, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.1 w/v %.

15. The method according to claim 14, wherein the pH is from about 7.5 to about 8.5.

16. The method according to claim 9, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4-bromobenzoyl phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) EDTA sodium salt; (f) benzalkonium cloride; (g) polyvinylpyrrolidone; and (h) sodium sulfite; and wherein the concentration of the 2-amino -3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.1 w/v %, and the concentration of tyloxapol is about 0.02 w/v %.

17. A method for treating an inflammatory disease of an eye, the method comprising administering to said eye a stable aqueous liquid preparation that comprises: (a) a first component; and (b) a second component; wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof; wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; the first component is the sole pharmaceutical active ingredient contained in the preparation and is present in the preparation at a concentration from about 0.05 w/v % to about 0.2 w/v %; the second component is tyloxapol; wherein said stable liquid preparation is formulated for ophthalmic administration; provided that the liquid preparation does not include mannitol; wherein said liquid preparation is administered to said eye at a dose and a frequency effective to treat said inflammatory disease; and wherein said inflammatory disease is blepharitis, conjunctivitis, scleritis or postoperative inflammatory.

18. The method according to claim 17, wherein said inflammatory disease is blepharitis, conjunctivitis or scleritis.

19. The method according to claim 17, wherein said Inflammatory disease is postoperative inflammation.

20. The method according to claim 17, wherein the stable aqueous liquid preparation further comprising a quaternary ammonium salt.

21. The method according to claim 17, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.

22. The method according to claim 17, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v % and the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 to about 0.1 w/v %.

23. The method according to claim 17, wherein the pH is from about 7.5 to about 8.5.

24. The method according to claim 17, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2 hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) EDTA sodium salt; (f) benzalkonium chloride; (g) polyvinylpyrrolidone; and (h) sodium sulfite; wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.02 w/v % to about 0.1 w/v %, and the concentration of tyloxapol is from about 0.02 w/v % to about 0.05 w/v %.

25. The method according to claim 17, wherein the stable aqueous liquid preparation is characterized in that greater than about 90% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks.

26. The method according to claim 25, wherein the stable aqueous liquid preparation further comprises a quaternary ammonium salt.

27. The method according to claim 25, wherein the stable aqueous liquid preparation is characterized in that greater than about 92% of the original amount of the first component remains in the preparation after storage at about 60.degree. C. for 4 weeks.

28. The method according to claim 25, wherein the concentration of tyloxapol is from about 0.01 w/v % to about 0.05 w/v %; and wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.1 w/v %.

29. The method according to claim 28, wherein the pH is from about 7.5 to about 8.5.

30. The method according to claim 17, wherein the stable aqueous liquid preparation consists essentially of: (a) 2-amino-3-(4bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, wherein the hydrate is at least one selected from a 1/2 hydrate, 1 hydrate, and 3/2hydrate; (b) tyloxapol; (c) boric acid; (d) sodium tetraborate; (e) EDTA sodium salt; (f) benzalkonium chloride; (g) polyvinylpyrrolidone; and (h) sodium sulfite; wherein said liquid preparation is formulated for ophthalmic administration; and wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 w/v % to about 0.1 w/v %.

31. The method of claim 1, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of US Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.

32. The method of claim 6, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of US Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.

33. The method of claim 9, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of US Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.

34. The method of claim 13, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of US Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.

35. The method of claim 17, wherein the aqueous liquid preparation further satisfies the preservative efficacy standard of US Pharmacopoeia as follows: viable cell counts of bacteria (S. aureus, P. aeruginosa) 24 hours and 7 days after inoculation decrease to not more than 1/10 and not more than 1/1000, respectively, and thereafter, the cell count levels off or decreases; and viable cell count of fungi (C. albicans, A. niger) 14 days after inoculation decreases to not more than 1/10, and thereafter, the cell count keeps the same level as that of 14 days after inoculation.

36. The method according to claim 1, wherein the stable aqueous liquid preparation further comprises one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

37. The method of claim 36, wherein said inflammatory disease is postoperative inflammation.

38. The method according to claim 9, wherein the stable aqueous liquid preparation further comprises one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

39. The method of claim 38, wherein said inflammatory disease is postoperative inflammation.

40. The method according to claim 17, wherein the stable aqueous liquid preparation further comprises one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

41. The method of claim 40, wherein said inflammatory disease is postoperative inflammation.

42. The method of claim 1, wherein said dose comprises one or two drops of the stable aqueous liquid preparation.

43. The method of claim 9, wherein said dose comprises one or two drops of the stable aqueous liquid preparation.

44. The method of claim 17, wherein said dose comprises one or two drops of the stable aqueous liquid preparation.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Harvard Business School
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.